Cabazitaxel for prostate cancer: Patient preparation and ongoing care

British Journal of Nursing

Volumn 21, Issue 9 SUPPL., 2012, Pages

  Hardwick, Julia ^a  

^a UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cabazitaxel; Nursing care; Patient education; Prostatic neoplasms

Indexed keywords

EID: 84861412740     PISSN: 09660461     EISSN: None     Source Type: Journal    
DOI: 10.12968/bjon.2012.21.sup6.s13     Document Type: Review

References (32)

1. Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15): 2433-53
2. Cancer Research UK (2010a) About hormone therapy for prostate cancer. http://tinyurl.com/82unecd (accessed 30 April 2012)
3. Cancer Research UK (2010b) The immune system. http://tinyurl.com/8yoaauj (accessed 26 April 2012)
4. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747): 1147-54
5. Dimeo FC (2001) Effects of exercise on cancer related fatigue. Cancer 92(6 Suppl): 1689-93
6. Eichenwald HF (2003) Fever and antipyresis. Bulletin of the World Health Organization 81(5): 372-3 Epub 2003 Jul 7.
7. Figg WD II, Figg WD Snr (2010) Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. Cancer Biol Ther 10(12): 1233-4
8. Kelly S, Wheatley D (2009) Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 101(Suppl 1): s6-s10
9. Kim SJ, Kim SI (2011) Current treatment strategies for castration-resistant prostate cancer. Korean J Urol 52(3): 157-65
10. Klastersky J, Paesmans M, Rubenstein EB (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16): 3038-51
11. Macmillan Cancer Support (2011) Peripheral neuropathy. http://tinyurl.com/cxrcuh4 (accessed 26 April 2012)
12. Marti Marti F, Cullen MH, Roila F (2009) Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol 20(Suppl 4): 166-9
13. Michielsen DPJ, Braeckman JG, Denis L (2011) Cabazitaxel for the treatment of prostate cancer. Expert Opin Pharmacother 12(6): 977-82
14. Middleton J, Lennan E (2011) Effectively managing chemotherapy-induced nausea and vomiting. Br J Nurs 20(17): S7-S14
15. Mita AC, Denis LJ, Rowinsky EK et al (2009) Phase I and pharmacokinetic study of XRP6258 (RPR116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15(2): 723-30
16. Multinational Association of Supportive Care in Cancer (2011) MASCC antiemetic guidelines. http://tinyurl.com/csvo6yx (accessed 26 April 2012)
17. National Confidential Enquiry into Patient Outcome and Death (2008) For better, for worse? http://tinyurl.com/ychptvo (accessed 26 April 2012)
18. National Institute for Health and Clinical Excellence (2006) Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. DH, London. http://tinyurl.com/cra4e6t (accessed 26 April 2012)
19. Oudard S (2011) TROPIC phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol 7(4): 497-506
20. Paller CJ, Antonarakis ES (2011) Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 5: 117-24
21. Portenoy RK, Itri LM (1999) Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4(1): 1-10
22. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1): 9-17
23. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5): v232-43
24. Saltz LB (2003) Understanding and managing chemotherapy induced diarrhea. J Support Oncol 1(1): 35-46
25. Sanofi (2011) Jevtana summary of product characteristics. http://tinyurl.com/cspy26s (accessed 26 April 2012)
26. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19): 3187-205
27. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S (2003) Cancer-related fatigue. Cancer 98(9): 1786-801
28. Tannock I F, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol 14(6): 1756-64
29. Tannock I F, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-12
30. U.S. Department of Health and Human Services (2009) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http://tinyurl.com/c2py9qr (accessed 26 April 2012)
31. Visovsky C (2003) Chemotherapy-induced peripheral neuropathy: nursing perspectives. Cancer Invest 21(3): 439-51
32. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11): 1507-15